 | Up a level |
Engert, A., Santoro, A., Shipp, M., Zinzani, P. L., Timmerman, J., Ansell, S., Armand, P., Fanale, M., Ratanatharathorn, V., Kuruvilla, J., Cohen, J., Collins, G., Savage, K., Trneny, M., Kato, K., Farsaci, B., Parker, S., Rodig, S. and Younes, A. (2016). CHECKMATE 205: A PHASE 2 STUDY OF NIVOLUMAB IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION AND BRENTUXIMAB VEDOTIN. Haematologica, 101. S. 319 - 320. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Zinzani, P. L., Engert, A., Younes, A., Santoro, A., Ansell, S., Timmerman, J., Collins, G., Armand, P., Savage, K. J., Trneny, M., Fanale, M., Kuruvilla, J., Cohen, J. B., Shipp, M., Rodig, S., Kato, K., Sumbul, A., Farsaci, B. A. and Ratanatharathorn, V. (2016). CHECKMATE 205 COHORT C: NIVOLUMAB IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA AFTER PRIOR BRENTUXIMAB VEDOTIN AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION. Haematologica, 101. S. 43 - 45. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078